Phase I lead-in to a 2x2x2 factorial trial of dose-dense temozolomide, memantine, mefloquine, and metformin as postradiation adjuvant therapy of glioblastoma (GBM).
Marta Penas-Prado
No relevant relationships to disclose
Morris D. Groves
Honoraria - Merck
Research Funding - Merck
Aaron G. Mammoser
No relevant relationships to disclose
Isaac Melguizo
No relevant relationships to disclose
John Frederick De Groot
Consultant or Advisory Role - Genentech; VBL Therapeutics
Honoraria - Merck
Research Funding - AstraZeneca; EMD Serono; Sanofi
Charles A. Conrad
No relevant relationships to disclose
Ivo Tremont-Lukats
No relevant relationships to disclose
Monica Elena Loghin
No relevant relationships to disclose
Vinay K. Puduvalli
Consultant or Advisory Role - Genentech; Novartis
Honoraria - Genentech; Novartis
Research Funding - Celgene; Genentech; Merck; Pfizer
Erik P. Sulman
Consultant or Advisory Role - GlaxoSmithKline
Honoraria - Merck
Kenneth R. Hess
No relevant relationships to disclose
Kenneth D. Aldape
No relevant relationships to disclose
Mark R. Gilbert
Consultant or Advisory Role - EMD Serono; Genentech; Merck; Novartis
Honoraria - EMD Serono; Genentech; Merck; Novartis
Research Funding - Genentech; GlaxoSmithKline; Merck
W. K. Alfred Yung
Consultant or Advisory Role - Actelion; Merck; Novartis
Honoraria - Merck; Novartis
Research Funding - Daiichi Sankyo